SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Science climbs as board approves incremental investments in Stelis

20 Sep 2019 Evaluate

Strides Pharma Science is currently trading at Rs. 371.10, up by 11.75 points or 3.27% from its previous closing of Rs. 359.35 on the BSE.

The scrip opened at Rs. 362.95 and has touched a high and low of Rs. 373.50 and Rs. 357.00 respectively. So far 134205 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 550.40 on 22-Jan-2019 and a 52 week low of Rs. 337.85 on 24-Jul-2019.

Last one week high and low of the scrip stood at Rs. 393.70 and Rs. 355.45 respectively. The current market cap of the company is Rs. 3341.09 crore.

The promoters holding in the company stood at 31.24%, while Institutions and Non-Institutions held 49.51% and 19.25% respectively.

Strides Pharma Science’s board has approved an additional investment up to a maximum of $40 million over a period of 24 months for a controlling stake in Stelis Biopharma (Stelis).

The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides’ re-entry into sterile injectables business post the completion of the company’s non-compete period in December 2019.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×